New data from rats and mice demonstrates that GLP-1s can support heart attack recovery by helping blood vessels ...

By using a mobile app and patient portal called MyQuest, “adult users can prompt the tool to define test names and medical ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial ...

The Department of Health and Human Services has told employees they can no longer use Claude, a generative AI tool from ...

After cutting down its pipeline just a few months ago, OSE Immunotherapeutics is at it again, this time reorganizing as ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a ...

Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its ...

Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin ...

T-cell engager (TCE) specialist Candid Therapeutics has entered a reverse merger agreement with Rallybio that will allow ...

BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets. | BioAtla ...

Over a year after first agreeing to a reverse merger with Pulmatrix, protein degradation biotech Cullgen has instead opted to ...

The Swiss drugmaker reported a phase 3 win for fenebrutinib over Sanofi's Aubagio in RMS in November. In that study, Roche ...